Amgen (AMGN) vs Bristol-Myers Squibb (BMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amgen (AMGN) has outperformed Bristol-Myers Squibb (BMY) over the past year, gaining 38.3% versus a gain of 33.8%. Over five years, AMGN leads with a +96.0% price change compared with +2.1% for BMY. Amgen is the larger company by market cap ($220.28 billion vs $121.70 billion), about 1.8 times the size.
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (9.0x vs 16.6x for Amgen). Bristol-Myers Squibb offers the higher dividend yield (4.21% vs 2.41%). Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 14.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | BMY |
|---|---|---|
| Share price | $407.44 | $59.58 |
| Market cap | $220.28B | $121.70B |
| 1-day change | -1.37% | -0.20% |
| YTD return | +24.48% | +10.46% |
| 1-year return | +38.29% | +33.77% |
| 5-year return | +96.04% | +2.09% |
| P/E ratio (TTM) | 25.31 | 13.12 |
| Forward P/E | 16.64 | 9.02 |
| EPS (TTM) | $16.10 | $4.54 |
| Dividend yield | 2.41% | 4.21% |
| Annual dividend | $9.80 | $2.51 |
| Revenue (latest FY) | $36.75B | $48.19B |
| Revenue growth (YoY) | +9.95% | -0.22% |
| Net income (latest FY) | $7.71B | $7.05B |
| Gross margin | 67.25% | 71.08% |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | 14.64% |
| 52-week high | $447.03 | $68.64 |
| 52-week low | $288.00 | $42.52 |
| Distance from 52-week high | -8.86% | -13.20% |
| Analyst consensus | hold | hold |
| Avg. price target upside | -3.92% | +11.06% |
| Average volume | 2.73M | 11.30M |
| Shares outstanding | 540.63M | 2.04B |
| Employees | 31,500 | 32,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen trades at a higher earnings multiple (25.3x vs 13.1x trailing P/E).
- Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.21% vs 2.41%).
- Amgen is more profitable, keeping 21.0 cents of every revenue dollar as net income versus 14.6 cents for Bristol-Myers Squibb.
- Amgen grew revenue faster in its latest fiscal year (+9.95% vs -0.22%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
AMGN vs BMY FAQ
Which is bigger, Amgen or Bristol-Myers Squibb?
Amgen (AMGN) is larger, with a market capitalization of $220.28B compared with $121.70B for Bristol-Myers Squibb (BMY).
Which stock has performed better over the past year, AMGN or BMY?
AMGN returned +38.29% over the past 12 months, compared with +33.77% for BMY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or BMY?
BMY has the lower trailing P/E at 13.1, versus 25.3 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Bristol-Myers Squibb?
Bristol-Myers Squibb has the higher yield at 4.21%, compared with 2.41% for Amgen.
Are Amgen and Bristol-Myers Squibb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Amgen and Biotechnology: Pharmaceutical Preparations for Bristol-Myers Squibb.